IL6 and neoplasm: Preclinical studies confirm that targeting IL-6/IL-6R reverses TME immunosuppression: IL-6 blockade combined with immunotherapy significantly enhances intratumoral T cell infiltration, dismantles immunosuppressive barriers, and restores anti-tumor immunity, thereby potentiating ICI efficacy and suppressing tumor progression in murine PC models (104, 105).